Staging exocrine pancreatic dysfunction

Area of Science:

• Gastroenterology
• Digestive Physiology
• Pancreatic Function

Background:

• Digestive capacity relies heavily on exocrine pancreatic function for nutrient absorption.
• Exocrine pancreatic insufficiency (EPI) impairs digestion, leading to steatorrhea and nutrient deficiencies.
• Fecal elastase 1 (FE1) is a common, though imperfect, non-invasive marker for pancreatic enzyme output.

Purpose of the Study:

• To propose a novel staging system for pancreatic exocrine dysfunction (EPD).
• To correlate FE1 levels, coefficient of fat absorption (CFA), and vitamin status for EPD classification.
• To guide management strategies, including pancreatic enzyme replacement therapy (PERT), based on EPD stage.

Main Methods:

• Proposed staging based on FE1 levels (mcg/gm), coefficient of fat absorption (CFA), and serum fat-soluble vitamin levels.
• Categorized EPD into four stages: Stage I (Mild), Stage II (Moderate), Stage III (Severe without deficiency), and Stage IV (Severe with deficiency).
• Differentiated between EPD and EPI, with EPI encompassing Stages III and IV.

Main Results:

• Stage I EPD (FE1 100-200 mcg/gm) and Stage II EPD (FE1 <100 mcg/gm without steatorrhea) are considered pancreas sufficient.
• Stage III EPD shows reduced FE1 and CFA but normal vitamin levels.
• Stage IV EPD presents with abnormal FE1, CFA, and vitamin levels, indicating nutritional deficiency.

Conclusions:

• EPD Stages I and II may not require immediate PERT, warranting further investigation into clinical utility.
• EPD Stages III and IV are defined as EPI and necessitate PERT.
• Stage IV EPI requires additional micronutrient supplementation alongside PERT.